Phase 2 N=56 Power Training Post-stroke
Stroke
Primary: Gait Speed — 0.51 meters per second
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
N/A N=4 Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
N/A N=15 Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Cerebral Palsy
Primary: Change in Assisting Hands Assessment Logit Score at End of Treatment — 2.63; 4.33 Scores on a scale
N/A N=20 Brain Stimulation and Hand Training in Children With Hemiparesis
Pediatric Hemiparesis
Primary: Change in Assisting Hand Assessment (AHA) — 6.4; 8; 5.5; 7.6 score on a scale
N/A N=96 Multimodal Treatment for Hemiplegic Shoulder Pain
Stroke · Shoulder Pain
Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) - Mean Change From Baseline — 7.1; 7.4; 8.1; -2.8 units on a scale
N/A N=44 Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy
Cerebral Palsy · Hemiplegia · Children
Primary: Change in Score on Assisting Hand Assessment (AHA) — 0.42; 0.56 score — p=<0.01
N/A N=32 Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
Cerebral Palsy Spastic Hemiplegic
Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale
Phase 3 N=388 Dysport® Adult Lower Limb Spasticity Study
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
N/A N=15 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
Hereditary Spastic Paraplegia · Adrenomyeloneuropathy
Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds
Phase 2 N=26 The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927…
N/A N=110 Functional Electrical Stimulation for Footdrop in Hemiparesis
Stroke · Hemiplegia
Primary: Fugl-Meyer Motor Assessment (FMA) — 20.1; 20.3; 21.5; 21.18 units on a scale
N/A N=10 Hand Function for Tetraplegia
Spinal Cord Injury · Tetraplegia
Primary: Grasp Release Test - Test of Functional Ability to Pick up and Move Objects — 2; 5.5 Number of Completions
N/A N=8 Noninvasive Spinal Stimulation in Stroke
Stroke
Primary: Change in Step-length Symmetry Using Symmetry Index — 72.2; 75.8; 92.2; 76.0 Symmetry Index
Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
N/A N=14 Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
Stroke
Primary: Fugl-Meyer Upper Extremity Assessment Part A — 4.13; 5.38; 0.88 score on a scale — p=<0.0001
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
N/A N=32 Dynamic Gait Index in Hemiplegic Cerebral Palsy
Cerebral Palsy · Hemiplegic Cerebral Palsy · Gait Disorders, Neurologic
Primary: Dynamic Gait Index (DGI) — 19; 24; 18.5 units on a scale — p=<0.01
Phase 3 N=345 Dysport® Adult Lower Limb Spasticity Follow-on Study
Post-stroke Spasticity · Spasticity Post-Traumatic Brain Injury
Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants
N/A N=34 Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke
Hemiparesis
Primary: Impairment in the Affected Upper Extremity as Measured by the Fugl Meyer Scale. — 19.6; 18.0; 17.6 units on a scale
N/A N=49 Progressive Supervised Home-based Strength Training in Children With Spastic Cerebral Palsy
Cerebral Palsy, Spastic
Primary: Change in Muscle Size Parameter — 3.7; 1.6; 1.4; 0.1 milliliters — p=<0.01
N/A N=51 Rotator Cuff Tears in Hemiplegic Shoulder
Hemiplegia
Primary: Rotator Cuff Tear of the Hemiplegic Shoulder, Confirmed by Ultrasonography — 29 participants
Phase 3 N=351 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Cerebral Palsy · Spasticity
Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017
Phase 3 N=258 Dysport® Adult Upper Limb Spasticity Extension Study
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
N/A N=44 A Pilot Study of Hand Function in Children With Cerebral Palsy Undergoing Intensive Neurophysiological Rehabilitation
Cerebral Palsy
Primary: Jebsen Taylor Hand Function Test for Dominant Hand — 130.1; 115.2 seconds
N/A N=27 Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy
Spastic Cerebral Palsy
Primary: Unit on Gross Motor Function Measure Scale (GMFM) — 5.12; 2.00 units on a scale — p=0.007
Phase 3 N=212 Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118
Phase 2 N=142 Study of SPARC1103 in Subjects With Spasticity
Spasticity
Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale
N/A N=58 Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model
Stroke
Primary: Change in Jebsen-Taylor Hand Function Test (JTHFT) Times From Baseline 2 to Post Test 1 — 5.07; -.11 seconds — p=<.05
N/A N=231 Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale